Most importantly, our data strongly suggest that the combined use of LOXL2 and ETFβ displayed a good predictive power to detect the early onset of DCM and as such, support that the disease progression can be slowed through early intervention. The gene discussed is LOXL2; the disease is familial dilated cardiomyopathy.